Novo Nordisk's Wegovy study hailed as 'heavyweight knockout' by Jefferies
Jefferies is not normally an advocate of Novo Nordisk shares, but it has difficulty finding any holes in Novo Nordisk’s cardiovascular study with the weight loss drug Wegovy.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.